Meeting
2017 ASCO Annual Meeting
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
Authors
Joyce F. Liu
Dana-Farber Cancer Institute, Boston, MA
Joyce F. Liu , William Thomas Barry , Michael J. Birrer , Jung-min Lee , Ronald J. Buckanovich , Gini F. Fleming , Bj Rimel , Mary K. Buss , Sreenivasa R. Nattam , Jean Hurteau , Weixiu Luo , Sarah Farooq , Christin Whalen , Elise C. Kohn , S. Percy Ivy , Ursula A. Matulonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT 01116648
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5535)
DOI
10.1200/JCO.2017.35.15_suppl.5535
Abstract #
5535
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
First Author: Joyce F. Liu
Poster
2014 ASCO Annual Meeting
Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).
First Author: Jung-min Lee
First Author: B.J. Rimel
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay